Physician profile
Roberto Alejandro Cruz Saldana
NPI 1285016899
$259,352.41
in general payments reported to CMS, 2019-2025
42 companies · $208K in 2025
The $208K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $600 · 2021: $1,615 · 2022: $1,973 · 2023: $5,443 · 2024: $39K · 2025: $208K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Consulting Fee: $65K · Travel and Lodging: $23K · Food and Beverage: $18K · Charitable Contribution: $2,070 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $144,751.00 |
| Consulting Fee | $64,940.64 |
| Travel and Lodging | $23,202.72 |
| Food and Beverage | $18,180.37 |
| Charitable Contribution | $2,070.00 |
| Education | $220.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $101,513.79 | 2019-2025 | Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $39,349.79 | 2019-2025 | Ultomiris |
| Amgen INC. | $39,290.49 | 2019-2025 | Uplizna |
| Tg Therapeutics, INC. | $35,812.51 | 2024-2025 | |
| Genzyme Corporation | $10,091.29 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $9,323.51 | 2020-2025 | Zeposia |
| Genentech USA, INC. | $7,966.88 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $2,407.64 | 2019-2025 | |
| Genentech, INC. | $2,214.42 | 2023-2025 | Ocrevus |
| Janssen Scientific Affairs, LLC | $1,425.16 | 2021-2025 | |
| Celgene Corporation | $1,332.09 | 2021-2025 | Zeposia |
| Biogen, INC. | $1,139.36 | 2019-2025 | Vumerity, Tysabri, Tecfidera |
| Medtronic, INC. | $928.49 | 2021-2024 | Percept Pc Brainsense, Sensight |
| Abbvie INC. | $912.30 | 2023-2025 | Ubrelvy, Botox, Qulipta |
| Horizon Therapeutics Plc | $761.09 | 2021-2023 | Uplizna |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $709.07 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Eisai INC. | $630.13 | 2019-2025 | |
| Argenx US, INC. | $581.10 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $396.64 | 2024-2025 | Vyepti |
| Janssen Biotech, INC. | $365.50 | 2025 | |
| Ani Pharmaceuticals, INC. | $298.97 | 2023-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $274.85 | 2024-2025 | Hyqvia |
| Janssen Pharmaceuticals, INC | $272.29 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $213.79 | 2025 | Ponvory |
| Pfizer INC. | $205.07 | 2024-2025 | |
| Lilly USA, LLC | $148.09 | 2024 | Kisunla, Amyvid, Emgality |
| Sk Life Science, INC. | $147.37 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $134.88 | 2022 | |
| Banner Life Sciences, LLC | $85.01 | 2023 | |
| Octapharma USA, INC. | $60.00 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Merck Sharp & Dohme LLC | $46.37 | 2023 | Reblozyl |
| Livanova USA, INC. | $44.76 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $37.82 | 2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $35.55 | 2024-2025 | Nuplazid |
| Grifols USA, LLC | $31.76 | 2024-2025 | Gamunex-C |
| Cycle Pharmaceuticals INC | $30.75 | 2025 | Tascenso Odt, Bafiertam |
| Jazz Pharmaceuticals INC. | $28.63 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $26.17 | 2024 | Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $22.28 | 2025 | Dysport |
| Sumitomo Pharma America, INC. | $21.98 | 2023 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $18.49 | 2025 | |
| Avanir Pharmaceuticals, INC. | $16.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Cruz Saldana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.